MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
GBS Total Assets 2011-2026 | GBS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets GBS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.25 M | 13.8 M | 10.4 M | 12.4 M | 21.9 M | 2.48 M | 2.33 M | 2.5 M | 667 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | 667 K | 8.28 M |
Quarterly Total Assets GBS
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 M | 8.25 M | 9.58 M | 8.68 M | 11.7 M | 13.8 M | 17 M | 8.83 M | 8.7 M | 10.4 M | 10.7 M | 18 M | - | 12.4 M | 14.4 M | 15.2 M | 19.1 M | 21.9 M | 21.9 M | 20 M | 2.48 M | 2.48 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 21.9 M | 2.48 M | 12.6 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
1.49 B | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
AxoGen
AXGN
|
204 M | $ 31.85 | 2.68 % | $ 1.41 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 8.97 | -1.59 % | $ 644 M |  Israel |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.89 | -2.51 % | $ 135 M | USA |
 |
Alphatec Holdings
ATEC
|
776 M | $ 16.95 | -4.48 % | $ 2.42 B | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 312.8 | -0.23 % | $ 8.83 B | USA |
 |
CONMED Corporation
CNMD
|
2.31 B | $ 41.19 | -0.91 % | $ 1.27 B | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.69 | -9.12 % | $ 138 M |  France |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 50.26 | 3.85 % | $ 7.49 K | USA |
 |
Boston Scientific Corporation
BSX
|
39.4 B | $ 91.09 | 3.43 % | $ 134 B | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
81.4 B | $ 121.01 | -0.61 % | $ 211 B | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
786 M | $ 13.79 | -1.11 % | $ 1.09 B | Israel |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
53.8 M | $ 27.84 | 0.04 % | $ 235 M | USA |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
6.21 B | $ 165.75 | -3.35 % | $ 12.4 B | USA |
 |
Accuray Incorporated
ARAY
|
470 M | $ 0.81 | -3.78 % | $ 83.2 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 13.82 | -5.67 % | $ 374 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.68 | 0.24 % | $ 122 M | USA |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 102.68 | 0.67 % | $ 1.3 B | USA |
 |
Integer Holdings Corporation
ITGR
|
3.08 B | $ 84.87 | -1.06 % | $ 2.85 B | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
LivaNova PLC
LIVN
|
2.51 B | $ 62.45 | 0.55 % | $ 3.39 B |  Britain |
 |
Globus Medical
GMED
|
5.25 B | $ 92.68 | -0.85 % | $ 12.6 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 11.98 | -3.51 % | $ 923 M | USA |
 |
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
163 M | $ 1.78 | 0.28 % | $ 69.6 M | USA |